{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":1,"podcast":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07751042\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["STX-003"],["STX-003","pembrolizumab"]],"indication":"advanced solid tumors","name":"ASCENT-1","nct_id":"NCT07751042","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ascent-1-nct07751042. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ASCENT-1","arms":[{"description":"STX-003 administered intravenously, at ascending doses across sequential cohorts, once per cycle for up to 35 cycles (approximately 24 months).","label":"Phase 1 Monotherapy","type":"EXPERIMENTAL"},{"description":"STX-003 administered intravenously, at ascending doses across sequential cohorts, once per cycle in combination with pembrolizumab for up to 35 cycles (approximately 24 months).","label":"Phase 1 Combination (STX-003 with Pembrolizumab)","type":"EXPERIMENTAL"},{"description":"STX-003 administered intravenously, at 4 planned dose expansion cohorts in patients with advanced cancers with high unmet need, once per cycle for up to 35 cycles (approximately 24 months).","label":"Phase 2 Monotherapy (STX-003)","type":"EXPERIMENTAL"},{"description":"STX-003 administered intravenously, at 4 planned dose expansion cohorts in patients with advanced cancers with high unmet need, once per cycle for up to 35 cycles (approximately 24 months).","label":"Phase 2 Combination (STX-003 with Pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-11-15","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":220,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"STX-003","otherNames":[],"type":"BIOLOGICAL"},{"name":"KEYTRUDA®","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-10-27","lead_sponsor":"Strand Therapeutics Inc.","official_title":"A Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of STX-003 Delivered Intravenously in Patients With Advanced Solid Tumors as a Monotherapy or in Combination With Pembrolizumab","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-07-17","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of TEAEs, SAEs, and DLTs","timeFrame":"From time of informed consent until 30 days after the last dose of investigational product."},{"measure":"Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-003.","timeFrame":"From Day 1 until 30 days after last dose of STX-003"}],"references":[],"start_date":{"date":"2026-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","url":"https://clinicaltrials.gov/study/NCT07751042"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ascent-1-nct07751042"}